[34] Omeprazole, esomeprazole and lansoprazole have a greater potential for drug–drug interactions than other PPIs. Pantoprazole is claimed to have a lower potential for drug–drug interactions ...

"AstraZeneca will have a strong base for considerable expansion ... In August 2000, Nexium (esomeprazole) for the treatment of acid-related diseases, such as gastrooesophageal reflux disease ...

Cipla is more likely to arise as one of the biggest beneficiaries of the issues plaguing its peers, provided its lower base, a strong pipeline will certainly benefit from the review cycles. With this, ...

Genetic polymorphisms have been described in the case of several CYP isoenzymes. The best explored example of this phenomenon is the CYP2C19 polymorphism. In this table the most frequent alleles ...